IMC Chicago’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.8M | Buy |
162,300
+48,600
| +43% | +$8.96M | 0.01% | 690 |
|
|
2025
Q4 | $20M | Buy |
113,700
+55,600
| +96% | +$9.08M | 0.01% | 851 |
|
|
2025
Q3 | $8.14M | Buy |
58,100
+14,500
| +33% | +$1.96M | ﹤0.01% | 1260 |
|
|
2025
Q2 | $5.48M | Sell |
43,600
-3,400
| -7% | -$424K | ﹤0.01% | 1334 |
|
|
2025
Q1 | $6.43M | Buy |
+47,000
| New | +$6.72M | ﹤0.01% | 1092 |
|
|
2024
Q2 | – | Sell |
-11,300
| Closed | -$2.44M | – | 2627 |
|
|
2024
Q1 | $2.44M | Sell |
11,300
-9,100
| -45% | -$2.13M | ﹤0.01% | 1271 |
|
|
2023
Q4 | $5.28M | Buy |
20,400
+8,600
| +73% | +$2.11M | ﹤0.01% | 868 |
|
|
2023
Q3 | $3.03M | Sell |
11,800
-6,300
| -35% | -$1.69M | ﹤0.01% | 874 |
|
|
2023
Q2 | $5.16M | Sell |
18,100
-38,000
| -68% | -$11.3M | ﹤0.01% | 668 |
|
|
2023
Q1 | $15.6M | Sell |
56,100
-32,100
| -36% | -$8.88M | 0.02% | 391 |
|
|
2022
Q4 | $24.4M | Sell |
88,200
-315,200
| -78% | -$89M | 0.04% | 273 |
|
|
2022
Q3 | $108M | Buy |
403,400
+361,500
| +863% | +$76.8M | 0.14% | 55 |
|
|
2022
Q2 | $8.54M | Buy |
41,900
+24,300
| +138% | +$4.97M | 0.01% | 465 |
|
|
2022
Q1 | $3.71M | Sell |
17,600
-109,400
| -86% | -$23.8M | ﹤0.01% | 617 |
|
|
2021
Q4 | $30.5M | Sell |
127,000
-13,900
| -10% | -$3.57M | 0.03% | 291 |
|
|
2021
Q3 | $39.9M | Sell |
140,900
-100,900
| -42% | -$33.1M | 0.04% | 221 |
|
|
2021
Q2 | $83.7M | Buy |
241,800
+189,000
| +358% | +$57.3M | 0.1% | 108 |
|
|
2021
Q1 | $14.8M | Sell |
52,800
-89,200
| -63% | -$24.1M | 0.02% | 362 |
|
|
2020
Q4 | $34.8M | Buy |
142,000
+66,700
| +89% | +$17.2M | 0.04% | 174 |
|
|
2020
Q3 | $21.4M | Buy |
75,300
+15,300
| +26% | +$4.27M | 0.03% | 193 |
|
|
2020
Q2 | $16.1M | Buy |
60,000
+25,300
| +73% | +$7.61M | 0.03% | 197 |
|
|
2020
Q1 | $11M | Sell |
34,700
-39,900
| -53% | -$12.1M | 0.02% | 205 |
|
|
2019
Q4 | $22.1M | Buy |
74,600
+30,600
| +70% | +$8.49M | 0.06% | 116 |
|
|
2019
Q3 | $10.2M | Sell |
44,000
-4,400
| -9% | -$1.02M | 0.03% | 179 |
|
|
2019
Q2 | $11.3M | Sell |
48,400
-4,400
| -8% | -$1.02M | 0.04% | 157 |
|
|
2019
Q1 | $12.5M | Buy |
52,800
+20,700
| +64% | +$6.52M | 0.04% | 118 |
|
|
2018
Q4 | $9.66M | Buy |
+32,100
| New | +$10.2M | 0.03% | 122 |
|
Other funds holding BIIB
VCM
VPM
IMC Chicago's BIIB Position: Q1 2026 in Review
IMC Chicago sold out of Biogen (BIIB) in Q1 2026, closing a stake of 19,011 shares — an estimated $3.5M sold.
IMC Chicago first reported a position in BIIB in Q4 2020 and held it in 5 quarters. The position peaked at $8.45M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- IMC Chicago reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 19,011 Biogen shares in Q1 2026, an estimated $3.5M.
- IMC Chicago first reported a position in Biogen in Q4 2020 and held it in 5 quarters.
- IMC Chicago's Biogen position peaked at $8.45M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.